Business Description
Boston Scientific Corp
NAICS : 339112
SIC : 3841
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Compare
Compare
Traded in other countries / regions
BSXC.Austria
•
B1SX34.Brazil
•
BSX.Germany
•
BSX.Mexico
•
BSX.Peru
•
0HOY.UK
•
BSX.USA
Description
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.58 | |||||
| Debt-to-EBITDA | 3.64 | |||||
| Interest Coverage | 3.75 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.75 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.8 | |||||
| 3-Year EBITDA Growth Rate | -1.4 | |||||
| 3-Year EPS without NRI Growth Rate | -16.6 | |||||
| 3-Year Book Growth Rate | 22.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 9.71 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 7.88 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.42 | |||||
| 9-Day RSI | 67.55 | |||||
| 14-Day RSI | 65.07 | |||||
| 6-1 Month Momentum % | -11.71 | |||||
| 12-1 Month Momentum % | -15.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | |||||
| Quick Ratio | 0.78 | |||||
| Cash Ratio | 0.08 | |||||
| Days Inventory | 146.26 | |||||
| Days Sales Outstanding | 51.03 | |||||
| Days Payable | 65.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.48 | |||||
| Operating Margin % | 15.71 | |||||
| Net Margin % | 7.17 | |||||
| ROE % | 5.08 | |||||
| ROA % | 2.79 | |||||
| ROIC % | 5.74 | |||||
| ROC (Joel Greenblatt) % | 52.45 | |||||
| ROCE % | 5.85 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 70.71 | |||||
| Forward PE Ratio | 23.31 | |||||
| PE Ratio without NRI | 70.71 | |||||
| Shiller PE Ratio | 172.67 | |||||
| Price-to-Owner-Earnings | 85.61 | |||||
| PEG Ratio | 11.38 | |||||
| PS Ratio | 4.78 | |||||
| PB Ratio | 3.5 | |||||
| Price-to-Free-Cash-Flow | 63.29 | |||||
| Price-to-Operating-Cash-Flow | 38.49 | |||||
| EV-to-EBIT | 42.05 | |||||
| EV-to-Forward-EBIT | 20.19 | |||||
| EV-to-EBITDA | 25.61 | |||||
| EV-to-Forward-EBITDA | 19.58 | |||||
| EV-to-Revenue | 5.52 | |||||
| EV-to-Forward-Revenue | 5.32 | |||||
| EV-to-FCF | 73.24 | |||||
| Price-to-Projected-FCF | 2.68 | |||||
| Price-to-Median-PS-Value | 1.17 | |||||
| Price-to-Peter-Lynch-Fair-Value | 14.65 | |||||
| Earnings Yield (Greenblatt) % | 2.39 | |||||
| Forward Rate of Return (Yacktman) % | 6.85 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:BSX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12,329 | ||
| EPS (TTM) ($) | 0.58 | ||
| Beta | 0.91 | ||
| Volatility % | 23.59 | ||
| 14-Day RSI | 65.07 | ||
| 14-Day ATR ($) | 0.849727 | ||
| 20-Day SMA ($) | 38.93 | ||
| 12-1 Month Momentum % | -15.43 | ||
| 52-Week Range ($) | 34.98 - 47.495 | ||
| Shares Outstanding (Mil) | 1,431.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Boston Scientific Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||